Literature DB >> 30031469

Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging.

Michael S Hofman1, Amir Iravani2, Tatenda Nzenza3, Declan G Murphy4.   

Abstract

Radiolabeled prostate-specific membrane antigen PET (PSMA PET) is emerging as an important modality for imaging prostate cancer (PCa). Promising clinical experience has led to increasing number of studies exploring the role of PSMA PET in different aspects of PCa including primary detection, risk stratification, targeted biopsy, initial staging, restaging at biochemical recurrence, biologic characterization, treatment response assessment and prognostication. PSMA PET may prove an important disease biomarker, expand our understanding of the pathogenesis and pave the way for personalized management of PCa.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PET; PSMA PET; PSMA PET/CT; Prostate cancer; Prostate-specific membrane antigen

Mesh:

Substances:

Year:  2018        PMID: 30031469     DOI: 10.1016/j.ucl.2018.03.016

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  6 in total

1.  Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study.

Authors:  Liran Domachevsky; Hanna Bernstine; Natalia Goldberg; Meital Nidam; Onofrio A Catalano; David Groshar
Journal:  Eur Radiol       Date:  2019-07-22       Impact factor: 5.315

2.  Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour.

Authors:  Mathieu Gaudreault; David Chang; Nicholas Hardcastle; Price Jackson; Tomas Kron; Michael S Hofman; Shankar Siva
Journal:  Clin Transl Radiat Oncol       Date:  2022-05-17

Review 3.  Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?

Authors:  Ramin Alipour; Arun Azad; Michael S Hofman
Journal:  Ther Adv Med Oncol       Date:  2019-09-20       Impact factor: 8.168

4.  Value of 11C-Choline PET/CT-Based Multi-Metabolic Parameter Combination in Distinguishing Early-Stage Prostate Cancer From Benign Prostate Diseases.

Authors:  Shuoming Zhou; Hongliang Fu; Changming Liu; Ziqiang Zhu; Jiabin Zhang; Wubin Weng; Jian Kang; Qiang Liu
Journal:  Front Oncol       Date:  2021-02-01       Impact factor: 6.244

5.  Utility of Biology-Guided Radiotherapy to De Novo Metastases Diagnosed During Staging of High-Risk Biopsy-Proven Prostate Cancer.

Authors:  Mathieu Gaudreault; David Chang; Nicholas Hardcastle; Price Jackson; Tomas Kron; Gerard G Hanna; Michael S Hofman; Shankar Siva
Journal:  Front Oncol       Date:  2022-04-12       Impact factor: 5.738

6.  Overexpression of prostate specific membrane antigen by canine hemangiosarcoma cells provides opportunity for the molecular detection of disease burdens within hemorrhagic body cavity effusions.

Authors:  Matthew Dowling; Jonathan Samuelson; Bahaa Fadl-Alla; Holly C Pondenis; Mark Byrum; Anne M Barger; Timothy M Fan
Journal:  PLoS One       Date:  2019-01-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.